Karachi: Otsuka Pakistan Limited has successfully navigated a complex business environment characterized by multiple operational challenges and stringent regulatory requirements, as outlined in their latest chairman's review for the financial year ending 2023-24.

During the 2023-24 financial period, Otsuka Pakistan faced significant operational disruptions primarily attributed to aging machinery and unforeseen global supply chain issues. Despite these hurdles, the company reported a marginal revenue growth, maintaining its commitment to product quality and safety, particularly in its intravenous solutions, which are critical in medical treatments across Pakistan.

According to information available from the Pakistan Stock Exchange (PSX), the board of directors at Otsuka Pakistan underwent significant changes, with new members elected at their Annual General Meeting held on October 8, 2024. These strategic changes in leadership are aimed at bolstering the company’s resilience and adapting more aggressively to the fast-evolving global pharmaceutical landscape.

Financially, the company observed a slight dip in profits, with earnings per share decreasing from Rs. 8.47 million in the previous year to Rs. 8.03 million. However, the company managed to maintain operational efficiency and manage costs effectively, achieving a net profit margin that remains competitive within the industry. This was despite the total revenue increasing to Rs. 12.18 billion compared to Rs. 11.89 billion in the prior year.

On the environmental and social responsibility front, Otsuka Pakistan has implemented robust measures to ensure the well-being and safety of their workforce and to minimize environmental impact. The initiatives focus on reducing waste and enhancing the health and hygiene levels at all of their facilities.

Looking forward, Otsuka Pakistan anticipates further challenges but remains committed to its strategic objectives, focusing on innovation in product development and enhancing market reach. The board is optimistic about the future, aiming to leverage their strong foundation to advance further in the pharmaceutical sector and continue providing high-quality healthcare products to the market.